Adjuvant enzalutamide for the treatment of early-stage androgen receptor-positive (AR+) TNBC.

Authors

Tiffany TrainaFollow
Leigh Ann BoyleFollow
Artavazd ArumovFollow
Sujata PatilFollow
Marcia EdelweissFollow
Patricia Anne DeFuscoFollow
Mila GorskyFollow
Nicholas Lamparella DO, Lehigh Valley Health NetworkFollow
Shanu Modi
Rachel Ann Sanford
Ayca GucalpFollow

Publication/Presentation Date

5-2019

Published In/Presented At

Traina, T., Boyle, L., Arumov, A., Patil, S., Edelweiss, M., DeFusco, P., Gorsky, M., Lamparella, N., Modi, S., Sanford, R., Gucalp, A. (2019, May). Adjuvant enzalutamide for the treatment of early-stage androgen receptor-positive (AR+) TNBC. Presentation presented at ASCO 2019 Annual Meeting, Chicago, IL.

Disciplines

Medicine and Health Sciences | Oncology

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Department of Medicine Faculty

Document Type

Presentation